Roche Won’t Change Avastin Price in UK, Despite NICE Cost-Effectiveness Decision
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche, Bayer, Pfizer and Wyeth weigh their responses to NICE’s statement that their products to treat advanced and/or metastatic kidney cancer are not cost effective.